Cargando…

Comparisons of Long-Term Survival and Safety of Haploidentical Hematopoietic Stem Cell Transplantation After CAR-T Cell Therapy or Chemotherapy in Pediatric Patients With First Relapse of B-Cell Acute Lymphoblastic Leukemia Based on MRD-Guided Treatment

Measurable residual disease (MRD) positivity before haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is an independent prognostic factor in determining outcomes in patients with B-cell acute lymphoblastic leukemia (ALL). In this study, we conducted a parallel comparison of the eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Guanhua, Cheng, Yifei, Zuo, Yingxi, Chang, Yingjun, Suo, Pan, Jia, Yueping, Lu, Aidong, Wang, Yu, Jiao, Shunchang, Zhang, Longji, Sun, Yuqian, Yan, Chenhua, Xu, Lanping, Zhang, Xiaohui, Liu, Kaiyan, Zhang, Leping, Huang, Xiaojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207442/
https://www.ncbi.nlm.nih.gov/pubmed/35734165
http://dx.doi.org/10.3389/fimmu.2022.915590
_version_ 1784729532508405760
author Hu, Guanhua
Cheng, Yifei
Zuo, Yingxi
Chang, Yingjun
Suo, Pan
Jia, Yueping
Lu, Aidong
Wang, Yu
Jiao, Shunchang
Zhang, Longji
Sun, Yuqian
Yan, Chenhua
Xu, Lanping
Zhang, Xiaohui
Liu, Kaiyan
Wang, Yu
Zhang, Leping
Huang, Xiaojun
author_facet Hu, Guanhua
Cheng, Yifei
Zuo, Yingxi
Chang, Yingjun
Suo, Pan
Jia, Yueping
Lu, Aidong
Wang, Yu
Jiao, Shunchang
Zhang, Longji
Sun, Yuqian
Yan, Chenhua
Xu, Lanping
Zhang, Xiaohui
Liu, Kaiyan
Wang, Yu
Zhang, Leping
Huang, Xiaojun
author_sort Hu, Guanhua
collection PubMed
description Measurable residual disease (MRD) positivity before haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is an independent prognostic factor in determining outcomes in patients with B-cell acute lymphoblastic leukemia (ALL). In this study, we conducted a parallel comparison of the efficacy and safety in patients with suboptimal MRD response after reinduction who underwent haplo-HSCT after chimeric antigen receptor T-cell (CAR-T) therapy or chemotherapy. Forty B-cell ALL patients who relapsed after first-line chemotherapy and with an MRD ≥0.1% after reinduction were analyzed. The median pre-HSCT MRD in the CAR-T group (n = 26) was significantly lower than that in the chemotherapy group (n = 14) (0.009% vs. 0.3%, p = 0.006). The CAR-T group exhibited a trend toward improved 3-year leukemia-free survival and a significantly improved 3-year overall survival compared to the chemotherapy group [71.8% (95% confidence interval (CI): 53.9–89.6) vs. 44.4% (95% CI: 15.4–73.4), p = 0.19 and 84.6% (95% CI: 70.6–98.5) vs. 40.0% (95% CI: 12.7–67.2), p = 0.008; respectively]. Furthermore, no increased risk of graft-versus-host disease, treatment-related mortality, or infection was observed in the CAR-T group. Our study suggests that CAR-T therapy effectively eliminates pre-HSCT MRD, resulting in better survival in the context of haplo-HSCT.
format Online
Article
Text
id pubmed-9207442
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92074422022-06-21 Comparisons of Long-Term Survival and Safety of Haploidentical Hematopoietic Stem Cell Transplantation After CAR-T Cell Therapy or Chemotherapy in Pediatric Patients With First Relapse of B-Cell Acute Lymphoblastic Leukemia Based on MRD-Guided Treatment Hu, Guanhua Cheng, Yifei Zuo, Yingxi Chang, Yingjun Suo, Pan Jia, Yueping Lu, Aidong Wang, Yu Jiao, Shunchang Zhang, Longji Sun, Yuqian Yan, Chenhua Xu, Lanping Zhang, Xiaohui Liu, Kaiyan Wang, Yu Zhang, Leping Huang, Xiaojun Front Immunol Immunology Measurable residual disease (MRD) positivity before haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is an independent prognostic factor in determining outcomes in patients with B-cell acute lymphoblastic leukemia (ALL). In this study, we conducted a parallel comparison of the efficacy and safety in patients with suboptimal MRD response after reinduction who underwent haplo-HSCT after chimeric antigen receptor T-cell (CAR-T) therapy or chemotherapy. Forty B-cell ALL patients who relapsed after first-line chemotherapy and with an MRD ≥0.1% after reinduction were analyzed. The median pre-HSCT MRD in the CAR-T group (n = 26) was significantly lower than that in the chemotherapy group (n = 14) (0.009% vs. 0.3%, p = 0.006). The CAR-T group exhibited a trend toward improved 3-year leukemia-free survival and a significantly improved 3-year overall survival compared to the chemotherapy group [71.8% (95% confidence interval (CI): 53.9–89.6) vs. 44.4% (95% CI: 15.4–73.4), p = 0.19 and 84.6% (95% CI: 70.6–98.5) vs. 40.0% (95% CI: 12.7–67.2), p = 0.008; respectively]. Furthermore, no increased risk of graft-versus-host disease, treatment-related mortality, or infection was observed in the CAR-T group. Our study suggests that CAR-T therapy effectively eliminates pre-HSCT MRD, resulting in better survival in the context of haplo-HSCT. Frontiers Media S.A. 2022-06-06 /pmc/articles/PMC9207442/ /pubmed/35734165 http://dx.doi.org/10.3389/fimmu.2022.915590 Text en Copyright © 2022 Hu, Cheng, Zuo, Chang, Suo, Jia, Lu, Wang, Jiao, Zhang, Sun, Yan, Xu, Zhang, Liu, Wang, Zhang and Huang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Hu, Guanhua
Cheng, Yifei
Zuo, Yingxi
Chang, Yingjun
Suo, Pan
Jia, Yueping
Lu, Aidong
Wang, Yu
Jiao, Shunchang
Zhang, Longji
Sun, Yuqian
Yan, Chenhua
Xu, Lanping
Zhang, Xiaohui
Liu, Kaiyan
Wang, Yu
Zhang, Leping
Huang, Xiaojun
Comparisons of Long-Term Survival and Safety of Haploidentical Hematopoietic Stem Cell Transplantation After CAR-T Cell Therapy or Chemotherapy in Pediatric Patients With First Relapse of B-Cell Acute Lymphoblastic Leukemia Based on MRD-Guided Treatment
title Comparisons of Long-Term Survival and Safety of Haploidentical Hematopoietic Stem Cell Transplantation After CAR-T Cell Therapy or Chemotherapy in Pediatric Patients With First Relapse of B-Cell Acute Lymphoblastic Leukemia Based on MRD-Guided Treatment
title_full Comparisons of Long-Term Survival and Safety of Haploidentical Hematopoietic Stem Cell Transplantation After CAR-T Cell Therapy or Chemotherapy in Pediatric Patients With First Relapse of B-Cell Acute Lymphoblastic Leukemia Based on MRD-Guided Treatment
title_fullStr Comparisons of Long-Term Survival and Safety of Haploidentical Hematopoietic Stem Cell Transplantation After CAR-T Cell Therapy or Chemotherapy in Pediatric Patients With First Relapse of B-Cell Acute Lymphoblastic Leukemia Based on MRD-Guided Treatment
title_full_unstemmed Comparisons of Long-Term Survival and Safety of Haploidentical Hematopoietic Stem Cell Transplantation After CAR-T Cell Therapy or Chemotherapy in Pediatric Patients With First Relapse of B-Cell Acute Lymphoblastic Leukemia Based on MRD-Guided Treatment
title_short Comparisons of Long-Term Survival and Safety of Haploidentical Hematopoietic Stem Cell Transplantation After CAR-T Cell Therapy or Chemotherapy in Pediatric Patients With First Relapse of B-Cell Acute Lymphoblastic Leukemia Based on MRD-Guided Treatment
title_sort comparisons of long-term survival and safety of haploidentical hematopoietic stem cell transplantation after car-t cell therapy or chemotherapy in pediatric patients with first relapse of b-cell acute lymphoblastic leukemia based on mrd-guided treatment
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207442/
https://www.ncbi.nlm.nih.gov/pubmed/35734165
http://dx.doi.org/10.3389/fimmu.2022.915590
work_keys_str_mv AT huguanhua comparisonsoflongtermsurvivalandsafetyofhaploidenticalhematopoieticstemcelltransplantationaftercartcelltherapyorchemotherapyinpediatricpatientswithfirstrelapseofbcellacutelymphoblasticleukemiabasedonmrdguidedtreatment
AT chengyifei comparisonsoflongtermsurvivalandsafetyofhaploidenticalhematopoieticstemcelltransplantationaftercartcelltherapyorchemotherapyinpediatricpatientswithfirstrelapseofbcellacutelymphoblasticleukemiabasedonmrdguidedtreatment
AT zuoyingxi comparisonsoflongtermsurvivalandsafetyofhaploidenticalhematopoieticstemcelltransplantationaftercartcelltherapyorchemotherapyinpediatricpatientswithfirstrelapseofbcellacutelymphoblasticleukemiabasedonmrdguidedtreatment
AT changyingjun comparisonsoflongtermsurvivalandsafetyofhaploidenticalhematopoieticstemcelltransplantationaftercartcelltherapyorchemotherapyinpediatricpatientswithfirstrelapseofbcellacutelymphoblasticleukemiabasedonmrdguidedtreatment
AT suopan comparisonsoflongtermsurvivalandsafetyofhaploidenticalhematopoieticstemcelltransplantationaftercartcelltherapyorchemotherapyinpediatricpatientswithfirstrelapseofbcellacutelymphoblasticleukemiabasedonmrdguidedtreatment
AT jiayueping comparisonsoflongtermsurvivalandsafetyofhaploidenticalhematopoieticstemcelltransplantationaftercartcelltherapyorchemotherapyinpediatricpatientswithfirstrelapseofbcellacutelymphoblasticleukemiabasedonmrdguidedtreatment
AT luaidong comparisonsoflongtermsurvivalandsafetyofhaploidenticalhematopoieticstemcelltransplantationaftercartcelltherapyorchemotherapyinpediatricpatientswithfirstrelapseofbcellacutelymphoblasticleukemiabasedonmrdguidedtreatment
AT wangyu comparisonsoflongtermsurvivalandsafetyofhaploidenticalhematopoieticstemcelltransplantationaftercartcelltherapyorchemotherapyinpediatricpatientswithfirstrelapseofbcellacutelymphoblasticleukemiabasedonmrdguidedtreatment
AT jiaoshunchang comparisonsoflongtermsurvivalandsafetyofhaploidenticalhematopoieticstemcelltransplantationaftercartcelltherapyorchemotherapyinpediatricpatientswithfirstrelapseofbcellacutelymphoblasticleukemiabasedonmrdguidedtreatment
AT zhanglongji comparisonsoflongtermsurvivalandsafetyofhaploidenticalhematopoieticstemcelltransplantationaftercartcelltherapyorchemotherapyinpediatricpatientswithfirstrelapseofbcellacutelymphoblasticleukemiabasedonmrdguidedtreatment
AT sunyuqian comparisonsoflongtermsurvivalandsafetyofhaploidenticalhematopoieticstemcelltransplantationaftercartcelltherapyorchemotherapyinpediatricpatientswithfirstrelapseofbcellacutelymphoblasticleukemiabasedonmrdguidedtreatment
AT yanchenhua comparisonsoflongtermsurvivalandsafetyofhaploidenticalhematopoieticstemcelltransplantationaftercartcelltherapyorchemotherapyinpediatricpatientswithfirstrelapseofbcellacutelymphoblasticleukemiabasedonmrdguidedtreatment
AT xulanping comparisonsoflongtermsurvivalandsafetyofhaploidenticalhematopoieticstemcelltransplantationaftercartcelltherapyorchemotherapyinpediatricpatientswithfirstrelapseofbcellacutelymphoblasticleukemiabasedonmrdguidedtreatment
AT zhangxiaohui comparisonsoflongtermsurvivalandsafetyofhaploidenticalhematopoieticstemcelltransplantationaftercartcelltherapyorchemotherapyinpediatricpatientswithfirstrelapseofbcellacutelymphoblasticleukemiabasedonmrdguidedtreatment
AT liukaiyan comparisonsoflongtermsurvivalandsafetyofhaploidenticalhematopoieticstemcelltransplantationaftercartcelltherapyorchemotherapyinpediatricpatientswithfirstrelapseofbcellacutelymphoblasticleukemiabasedonmrdguidedtreatment
AT wangyu comparisonsoflongtermsurvivalandsafetyofhaploidenticalhematopoieticstemcelltransplantationaftercartcelltherapyorchemotherapyinpediatricpatientswithfirstrelapseofbcellacutelymphoblasticleukemiabasedonmrdguidedtreatment
AT zhangleping comparisonsoflongtermsurvivalandsafetyofhaploidenticalhematopoieticstemcelltransplantationaftercartcelltherapyorchemotherapyinpediatricpatientswithfirstrelapseofbcellacutelymphoblasticleukemiabasedonmrdguidedtreatment
AT huangxiaojun comparisonsoflongtermsurvivalandsafetyofhaploidenticalhematopoieticstemcelltransplantationaftercartcelltherapyorchemotherapyinpediatricpatientswithfirstrelapseofbcellacutelymphoblasticleukemiabasedonmrdguidedtreatment